The results showed that the CD8+ T population in the patient PBMCs was similar to that of the healthy donors (23.8 ± 1% and 25.7 ± 1%, respectively), whereas the presence of CD8+ TILs (6.5 ± 1%) was significantly lower in the glioma microenvironment compared to HD PBMCs (Figures 2A,B). This evidence concerns the gene CD8A and central nervous system cancer.